While we’re weary to promote any kind of ‘quick fix’ weight loss pill, the “Take Five to Live Light” campaign is something we’re a little more willing to get behind.
The campaign is part of a study that’s investigating a new weight loss drug called Contrave, which has been in development for the last several years.
Contrave is a combination of two medications – naltrexone and bupropion – which have long-been prescribed to patients to aid weight loss. While the two haven’t been found dangerous on their own, the study is seeking to confirm that pairing the two won’t have any adverse affects on patients.
Steven R. Smith, M.D., scientific director of the Florida Hospital, believes that most people can’t achieve long term weight loss through diet and exercise alone, saying “the Light Study is an important clinical research study evaluating the cardiovascular health outcomes of Contrave, which is designed to reduce appetite, increase metabolism, and control cravings and overeating behaviors.” (more…)
The pharmaceutical company Orexigen Therapeutics reached an agreement with the U.S. Food and Drug Administration for a heart-safety trial of the obesity drug Contrave. Regulatory officials worry that the previously rejected experimental drug may increase cardiovascular risks, which the placebo-controlled trial has been designed to measure.
The trial will enroll 10,000 patients and will study the long-term affects of Contrave on the heart. The trial has been designed under a “special protocol assessment” from the FDA, which indicates that the agency approves of that trial. If the trials succeed in showing that there in no increased danger of cardiovascular events associated with the diet drug, it is expected that Contrave will be approved. Orexigen has partnered with Takeda Pharmaceutical Co. to help develop the drug for the U.S., Mexico and Canada.
Diet pills are most often stimulants, working to decrease your appetite, curb cravings and boost your metabolism. Sold over the counter, they often have no regulation from the FDA and are often subject to recalls and lawsuits. The two most notable diet pills to have been approved by the FDA, Xenical and Meridia, have been riddled with problems and Meridia has been withdrawn. Most diet pills are taken off the market within five years of FDA approval. Almost all of them are taken off the market for increased heart risks and have even been linked to deaths.
However, there is a new diet pill on the horizon, set to be approved by the FDA as early as next month, and it is a different type all together. A combination of an antidepressant and an anti-addiction medication, Contrave is the newest and most exciting weight loss drug to hit the market in recent years.
UPDATE: FDA Rejects Qnexa (7/16/2010)
The Huffington Post reported that on Monday, the Food and Drug Administration is expected to release the review of Vivus Inc.’s pill, Qnexa. The first of three new weight loss drugs to be assessed by the FDA, Qnexa showed promising results in clinical trials. Patients lost between 13 and 15 percent of their body weight, but many who began the trial dropped out due to side effects, which included memory and concentration problems. (more…)
In a clinical study that has left researchers baffled, the new weight loss drug Contrave exceeded the U.S. Food and Drug Administration’s requirements to prove a weight loss drug’s efficacy. Contrave is actually a combination of two different drugs: bupropion and naltrexone, which are used to fight depression and smoking addiction respectively. This combination of pharmaceuticals is often prescribed in the treatment of alcohol and opiate addiction.